May 19, 2020 08:30 ET
| Source: T2 Biosystems, Inc.
LEXINGTON, Mass., May 19, 2020 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the speedy detection of sepsis-causing pathogens, today announced it won the “Best New Technology Solution – Diagnostics” award for its T2Bacteria® Panel solution in the fourth annual MedTech Breakthrough Awards program. The awards program, which received thousands of nominations from agencies across the globe, “recognizes the top businesses, people, platforms and products in the health, fitness and medical technology industries today,” according to its website. “We’re venerated to be diagnosed by means of the MedTech Breakthrough Awards and grateful to the judges who admire the importance of speedy identity of sepsis-causing pathogens in order to with ease and efficaciously treat patients with bloodstream infections, which can lead to sepsis,” stated John Sperzel, President and Chief Executive Officer of T2 Biosystems. Sperzel continued, “According to the Centers for Disease Control and Prevention, both year at least 1.7 million adults in America increase sepsis and virtually 270,000 Americans die as a result. But, with quick diagnosis and treatment, which our T2Bacteria Panel facilitates facilitate, we can aid reduce those numbers for patients with bloodstream infections and improve patient outcomes.” The T2Bacteria Panel, which was FDA cleared in May 2018, can become aware of sepsis-causing bacterial pathogens without delay from whole blood in three to five hours, without the want to wait for a blood culture, which typically takes days to supply effects and is not as sensitive. By offering quicker effects, the T2Bacteria Panel can aid clinicians start patients on the right remedy sooner, which can lead to a series of potential merits, adding superior patient outcomes, higher management of antibiotics, reduced length of live in the medical institution and more. The MedTech Breakthrough Award is one more addition to the Company’s transforming into list of accolades and milestones. Most recently, T2 Biosystems announced it became awarded an Innovative Technology agreement from Vizient, Inc., the largest member-driven health care functionality advantage company in the country, covering its T2Dx® Instrument, as smartly as the T2Bacteria and T2Candida® Panels. About T2 Biosystems T2 Biosystems, a leader in the swift detection of sepsis-causing pathogens, is committed to convalescing patient care and cutting back the cost of care by way of aiding clinicians readily treat patients quicker than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, and the T2Resistance™ Panel and are powered by capacity of the proprietary T2 Magnetic Resonance (T2MR®) era.
T2 Biosystems has an active pipeline of destiny products, including the T2Cauris™ Panel, T2SARS-CoV-2™ Panel, and T2Lyme™ Panel, as smartly as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, as neatly as biothreat pathogens. Forward-Looking StatementsThis press free up includes ahead-looking statements inside the that ability of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press unlock that do no longer relate to matters of historic statement need to be judicious forward-shopping statements, adding, without limitation, statements concerning additional patients, timing of checking out patients, expected product advantages, strategic priorities, product expansion or opportunities, boom expectations or targets, timing of FDA filings or clearances and anticipated running expenses, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may also,” “need to,” “anticipate,” and identical statements of a destiny or forward browsing nature. These ahead-shopping statements are based on control’s existing expectancies.
These statements are neither gives you nor guarantees, having said that involve popular and unknown risks, uncertainties and other essential elements that may also lead to accurate consequences, performance or achievements to be materially alternative from any destiny outcomes, performance or achievements expressed or implied by way of the ahead-searching statements, adding, nevertheless now not limited to, (i) any inability to (a) observe expected advantages from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) strengthen product usage or adoption; (e) obtain purchaser testimonials; (f) as it should be are expecting boom assumptions; (g) notice anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at buyer facilities; (ii) failure of early information to are expecting eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed below Item 1A.
“Risk Factors” in the agency’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, or SEC, on March 16, 2020, and other filings the company makes with the SEC from time to time. These and other vital elements may cause exact results to fluctuate materially from the ones indicated by means of the forward-shopping statements made in this press free up.
Any such forward-browsing statements represent management’s estimates as of the date of this press unencumber.
While the agency also can go with to update such forward-browsing statements at a few point in the destiny, unless required via law, it disclaims any duty to do so, even if next routine cause its perspectives to change. Thus, no one need to expect that the Company’s silence over time capacity that exact hobbies are bearing out as expressed or implied in such forward-shopping statements. These ahead-looking statements should now not be relied upon as representing the company’s perspectives as of any date subsequent to the date of this press unencumber.
Media Contact: Gina Kent, Vault 610-455-2763 Investor Contact:Philip Trip Taylor, Gilmartin
Lexington, Massachusetts, UNITED STATES
LOGO URL | Copy the link below